LENZ (LENZ Therapeutics) Tariff Resilience Score: 5/10 (As of Jul. 06, 2026)


LENZ LENZ Therapeutics Inc LENZ
12 GF Score
Price $5.89
! 2 Warning Signs
View Full Analysis

What is LENZ Therapeutics Tariff Resilience Score?

LENZ Therapeutics LENZ +1.73% 12 Tariff Resilience Score is 5 as of Jul. 06, 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,369 Biotechnology companies, LENZ Therapeutics ranks better than 62.38% on this metric.

LENZ Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

LENZ Therapeutics has LENZ Therapeutics, as a biotech firm, faces potential tariff risks on imported raw materials and equipment. The company has limited pricing power but can explore alternative suppliers. Industry-specific exemptions may apply.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes LENZ Therapeutics might have Average Resilient.

LENZ Therapeutics  (NAS:LENZ) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

LENZ Therapeutics Tariff Resilience Score Related Terms

LENZ vs KRRO, ANTX, OKUR: Tariff Resilience Score Comparison

For the Biotechnology subindustry, LENZ Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LENZ Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where LENZ Therapeutics's Tariff Resilience Score falls into.


LENZ
12GF Score
LENZ Therapeutics Inc LENZ
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
LENZ Therapeutics (LENZ) has a Tariff Resilience Score of 5 as of Jul. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, LENZ Therapeutics ranks #515 out of 1369 companies in the Biotechnology industry, placing it in the top 37.6%.
Is LENZ Therapeutics' Tariff Resilience Score too high?
LENZ Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. LENZ Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, LENZ Therapeutics ranks #515 out of 1369 companies in the Biotechnology industry, which is above the industry midpoint. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' Tariff Resilience Score compare to KRRO and ANTX?
According to the Biotechnology industry distribution chart, LENZ Therapeutics ranks #515 out of 1369 companies for Tariff Resilience Score. This puts LENZ Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. LENZ Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LENZ Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LENZ Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current Tariff Resilience Score is 5 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LENZ Therapeutics Business Description

Address 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score

Get the complete analysis for LENZ

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.89
Price